Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNOVALYTE IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SYNOVALYTE is a hyaluronan preparation that acts as a viscoelastic supplement, restoring the rheological properties of synovial fluid in osteoarthritic joints. It provides lubrication and shock absorption, and may exert anti-inflammatory and analgesic effects through modulation of synovial fluid viscosity and interaction with hyaluronan receptors.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intra-articular injection: 2 m L per joint once weekly for 3 weeks.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Not applicable; components (sodium, chloride, lactate) are endogenous and rapidly redistributed; lactate half-life ~5-10 minutes in normal hepatic function.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Hyaluronan is primarily metabolized in the liver and synovium via hyaluronidases and subsequent breakdown into constituent monosaccharides.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Renal excretion of sodium, chloride, and lactate; not metabolized; elimination routes not quantified as it is a crystalloid solution.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Not bound; sodium, chloride, and lactate are free in plasma.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Sodium and chloride distribute in extracellular fluid (Vd ~0.2 L/kg); lactate distributes in total body water (Vd ~0.6 L/kg).
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Intravenous: 100% (by definition); not administered by other routes.
100% intravenous; not administered by other routes.
No dosage adjustment required in renal impairment.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No dosage adjustment required in hepatic impairment.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Safety and efficacy not established in pediatric patients.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
No specific dosage adjustment required; use caution due to potential comorbidities.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
None.
Not applicable; no FDA boxed warning exists for this product.
Do not use in patients with known hypersensitivity to hyaluronan preparations.,Post-marketing reports of anaphylactoid reactions, including cases of cardiac arrest and death.,Use caution in patients with active joint infections or skin diseases at the injection site.,Effusion may occur post-injection; warn patients to avoid strenuous activities for 48 hours.,Repeated intra-articular injections may increase risk of adverse events.
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Known hypersensitivity to hyaluronate preparations.,Active joint infection or skin infection at the injection site.
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No known food interactions. Maintain normal diet unless instructed otherwise by physician.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
No teratogenic risk expected as Synovalyte (hyaluronate sodium) is a large molecular weight polysaccharide that does not cross the placenta. No fetal risk identified in animal studies.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Not expected to be excreted in breast milk due to high molecular weight. M/P ratio not available; use with caution in nursing mothers.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No dose adjustment required as pharmacokinetics are not altered by pregnancy; systemic absorption is negligible.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
Synovalyte in plastic container is a sterile, non-pyrogenic irrigating solution for intraoperative joint irrigation. Use only if solution is clear and container undamaged. Discard any unused portion; no preservatives. Monitor for fluid overload in patients with renal impairment or heart failure. Do not administer intravenously.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This solution is used during surgery to wash the joint area.,You may experience temporary swelling or discomfort after irrigation.,Report any signs of infection like increased pain, redness, or fever.,Follow your surgeon's post-operative instructions carefully.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNOVALYTE IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
SYNOVALYTE IN PLASTIC CONTAINER is a Electrolyte Solution that works by SYNOVALYTE is a hyaluronan preparation that acts as a viscoelastic supplement, restoring the rheological properties of synovial fluid in osteoarthritic joints. It provides lubrication and shock absorption, and may exert anti-inflammatory and analgesic effects through modulation of synovial fluid viscosity and interaction with hyaluronan receptors.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNOVALYTE IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNOVALYTE IN PLASTIC CONTAINER is: Intra-articular injection: 2 m L per joint once weekly for 3 weeks.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNOVALYTE IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNOVALYTE IN PLASTIC CONTAINER is classified as Category C. No teratogenic risk expected as Synovalyte (hyaluronate sodium) is a large molecular weight polysaccharide that does not cross the placenta. No fetal risk identified in animal stud. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.